Agora Financial New Ultra-Wealth Stock. Any idea of this stock name and value ?

5 responses to “ Agora Financial New Ultra-Wealth Stock. Any idea of this stock name and value ?”

1. robinsteel says:

   October 14, 2014 at 6:20 pm

   So where is the picture? what is the stock? I don’t think that Joe is going to join this thread, so we need the thinkalator to find out more…can anyone figure out how to put the picture up on this thread? Then we can make our guesses, I guess.

   Reply
   • Dave says:

     October 30, 2014 at 8:14 pm

     I know of one it is bio time BTX. In the video from Argora Financial I believe about five minutes in they show a beating heart cell in a petri dish from one of the skin cells from someone with in their hedge fund that person was Patrick Cox. He went to bio time and had a skin cell from under his arm removed and then reprogrammed those cells with pluripotent stem cells into a Heart cell… They showed the cells beating under a microscope… As to the other four companies they talk about I think one could possibly be
     CYTX… Still searching for the other three

     Reply
2. Travis Johnson, Stock Gumshoe says:

   October 14, 2014 at 7:09 pm

   The ad’s here, I haven’t read it yet: http://research.agorafinancial.com/research/html/vpi_33people_0914/

   Reply
3. fpriestly says:

   October 28, 2014 at 2:39 pm

   I’ll take a shot and say that one of the stocks he’s touting is Zimmer Holdings, Inc. (ZMH) -NYSE currently trading at $107.74, really expensive but has some potential to gain if you are the buy and hold type. Zimmer is a good read but my opinion is these guys will be out on the limb for a long time on this one, See the bouncing trades on the technology below:
   This is one of the Emerging Technologies That Will Change the World
   Listed in the TECHNOLOGY REVIEW February 2003 concerning Injectable Tissue Engineering
   http://www2.technologyreview.com/featured-story/401775/10-emerging-technologies-that-will-change-the/3/
   This is bascially about injectable tissues research led by Jennifer Elisseeff, a biomedical engineer at Johns Hopkins University, She and her colleagues have developed a way to inject joints with specially designed mixtures of polymers, cells, and growth stimulators that solidify and form healthy tissue. The researchers added cartilage cells to a light-sensitive liquid polymer and injected it under the skin on the backs of mice. They then shone ultraviolet light through the skin, causing the polymer to harden and encapsulate the cells. Over time, the cells multiplied and developed into cartilage. To test the feasibility of the technique for minimally invasive surgery, the researchers injected the liquid into the knee joints of cadavers. The surgeons used a fiber-optic tube to view the hardening process on a television monitor. “This has huge implications,” says James Wenz, an orthopedic surgeon at Johns Hopkins who is collaborating with Elisseeff. They made layers of a polymer-and-stem-cell mixture, infusing each layer with specific chemical signals that triggered the cells to develop into either bone or cartilage. Such hybrid materials would simplify knee replacement surgeries, for instance, that require surgeons to replace the top of the shin bone and the cartilage above it. But and this is a huge but, Don’t expect tissue engineers to grow entire artificial organs anytime soon. Elisseeff, for one, is aiming for smaller advances that will make tissue engineering a reality within the decade. For the thousands of U.S. patients who need new joints every year, such small feats could be huge. – Alexandra M. Goho
   Jennifer Elisseeff, also cofounded Cartilix and Elisseeff is also a member of Technology Review’s TR35 in 2002, and her team have tested the material in rabbits and goats and have found that more cells from the bone marrow get trapped in the blood clot when the hydrogel is present, compared with microfracture conducted without the gel. The researchers also noted that the defects fill faster with the biomaterial than without, and that the newly formed tissue more closely resembles true cartilage.
   THIS IS WHERE IT GETS MORE INTERESTING
   Results from a small clinical trial in Europe also look promising. According to findings presented at EmTech, magnetic resonance scans of the knee six months after the procedure showed that patients who received the hydrogel had grown more tissue than those undergoing traditional microfracture, and they reported less pain. Cartilix hopes to submit the data from its European study to the U.S. Food and Drug Administration (FDA) and begin a larger human trial in the United States.
   Elisseeff is adapting her biomaterials for other applications as well. For instance, she recently licensed some of her technology to Kythera Biopharmaceuticals, a company based in Calabasas, CA, that specializes in cosmetic medicine. The company is using Elisseeff’s materials to develop light-activated cosmetic fillers that last much longer than those currently on the market. These fillers, which are typically injected into the skin along the sides of the mouth to minimize wrinkles caused by aging, tend to have a short life span. Patients often have the procedure repeated several times a year.
   “With our materials, we shine light over [the area of the skin] that was injected and cross-link the materials so that they don’t degrade as quickly,” says Elisseeff. She says that Kythera plans to test the cosmetic fillers in patients in a couple of months. The first pilot study will take place in Beverly Hills. KYTHERA NASDAQ: KYTH current Price: 36.87
   Marcus, who is chief medical officer at Cartilix, and his colleagues hope to improve the procedure and make it more accessible to the larger population of baby boomers. As people age, many are forced to curtail their physical activities due to painful, swollen joints caused by the deterioration of cartilage in the knee that comes with age or results from repetitive stress or injury. Marcus hopes to be able to treat these patients before they develop full-blown osteoarthritis. “The goal is to identify that big population that wants to be active throughout their entire lives,” he says.
   During microfracture, a surgeon uses a special awl to drill a series of tiny holes into the bone underneath the area of missing cartilage. Bone marrow containing stem cells seeps into the damaged area and forms a clot. The clot releases stem cells, which differentiate into cartilage cells and gradually form new tissue. However, because the new tissue is scar cartilage, not true cartilage, it may not have the same durability and strength as the original tissue–a likely contributor to the high
   The plot thickens…. BEST INTENTIONS

   Biomet announces aquisition of the assets of cartilage repair company Cartilix
   http://www.bizjournals.com/sanfrancisco/stories/2009/11/09/daily7.html

   October 20, 2009
   Warsaw, IN, October 20, 2009—Biomet, Inc., a global leader in the manufacture of orthopedic and dental medical devices, announced today its acquisition of the assets of Cartilix, a Foster City, CA based company that has developed proprietary cartilage repair technology. Cartilix was founded in 2004 to develop cartilage repair and regeneration solutions. The Cartilix technology provides Biomet with an opportunity to facilitate earlier intervention in pre-arthritic patients.” LEAD TO LAWSUITS FOR COMPANY
   http://www.biomet.com/fileLibrary/corporate/investors/financials/May%2031%202009%2010-K.pdf
   FINALLY…. A profits made and this technology is still unproven…
   Zimmer Holdings, Inc. to Combine with Biomet, Inc. in Transaction Valued at $13.35 Billion
   http://www.reuters.com/finance/stocks/overview?symbol=ZMH&lc=int_mb_1001
   (WARSAW, IN) April 24, 2014 – Zimmer Holdings, Inc. (NYSE and SIX: ZMH) (“Zimmer” or the “Company”) and Biomet, Inc.’s parent company (“Biomet”) today announced that their respective Boards of Directors have approved a definitive agreement under which Zimmer will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the first quarter of 2015.

   Like I said, these guys are making a strong push at the number two spot in the market but this technology will take a long time to become profitable, I put it in my watchlist for future consideration

   Reply
4. spam victim says:

   December 19, 2014 at 4:39 pm

   Joe Schriefer from Agora Financial is just another scum-sucking maggot from the Internet underworld.

   I receive his never-ending garbage spam on a daily basis to a dozen email addresses, always from a newly registered domain. His scumbag staff wants more identification before allowing any communications. Anyone in business that relies on this intensely aggrivating marketing must be very bad at his work.

   Any other victims out there?

   Want to sue him?

   Drop dead, Joe.

   Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Copyright ©2024 Stock Gumshoe unless otherwise noted.